A double‐blind, randomized, placebo‐controlled, phase 2 trial also showed that IL‐6 inhibition with ziltivekimab markedly reduced biomarkers of inflammation and thrombosis relevant to atherosclerosis in patients with advanced chronic renal disease.39 This evidence concerns the gene IL6 and atherosclerosis.